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Abstract
Background: Survival after childhood cancer has improved to more than 80% during the last few years, leading to an increased
number of childhood cancer survivors. Cancer itself, or its treatment, may cause chronic health conditions, including somatic and
mental sequelae, which may affect survivors’ health-related quality of life (HRQoL).
Objective: The project PanCareLIFE aims to establish a large database with comprehensive data on childhood cancer survivors
from different European countries, including data on HRQoL. Within PanCareLIFE, this study aims to describe HRQoL in
survivors, investigate predictors of HRQoL, and describe the association of HRQoL with hearing and female fertility impairment.
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This paper describes the design of the HRQoL study, the origin of data, strategies for data collection, and sampling characteristics
of survivors from each contributing country.
Methods: A total of 6 institutions from 5 European countries (the Czech Republic, France, Germany, the Netherlands, and
Switzerland) provided data on HRQoL assessed with the Short Form 36 and on relevant predictors. The central PanCareLIFE
data center aggregated the data and harmonized the variables between the institutions. Survivors were eligible if they received a
diagnosis of cancer according to the 12 main groups of the International Classification of Childhood Cancer, 3rd edition, or
Langerhans cell histiocytosis; were aged ≤18 years at the time of diagnosis; were residents of the respective country at the time
of diagnosis; had survived ≥5 years after cancer diagnosis; were aged ≥18 years at the time of the questionnaire survey; and did
not refuse to registration in the national or local childhood cancer cohort.
Results: We identified 24,993 eligible survivors. Of those, 19,268 survivors received a questionnaire and 9871 survivors
participated, resulting in response rates of 9871/24,993 (39.50%) of eligible survivors and of 9871/19,268 (51.23%) invited
survivors. Most participants were diagnosed with cancer between the ages of 10 and 14 years (3448/9871, 34.93%) or <5 years
(3201/9871, 32.43%). The median age was 8 years. Of the 9871 participants, 3157 (31.97%) were survivors of leukemia, 2075
(21.02%) lymphoma, and 1356 (13.7%) central nervous system (CNS) tumors. Most participants (9225/9871, 93.46%) had no
history of a subsequent tumor; 77.45% (7645/9871) received chemotherapy with or without other treatments. More than half
(5460/9871, 55.31%) were aged 25 to 34 years at the time of the HRQoL study. Participating survivors differed from nonparticipants;
participants were more often women, survivors of leukemia or lymphoma, and less frequently, survivors of CNS tumors than
nonparticipants.
Conclusions: PanCareLIFE successfully assessed HRQoL and its predictors in 9871 European survivors of childhood cancer.
This large population will permit detailed investigations of HRQoL after childhood cancer, particularly the impact of hearing
and female fertility impairment on HRQoL.
International Registered Report Identifier (IRRID): RR1-10.2196/21851
(JMIR Res Protoc 2021;10(1):e21851) doi: 10.2196/21851
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Introduction
At present, more than 80% of children diagnosed as having
cancer in Europe survive [1]. Almost half a million childhood
cancer survivors are estimated to live in Europe in 2020 [2].
However, cancer itself, or its treatment, causes chronic health
conditions, including a broad spectrum of somatic [3] and mental
sequelae [4]. In the St. Jude Lifetime Cohort Study, nearly all
childhood cancer survivors had at least one chronic health
condition by the age of 50 years and twice the burden of disease
than the general population [5]. Chronic health conditions such
as heart failure, second neoplasms, or pulmonary dysfunction
can be life threatening; other health conditions such as fertility
and hearing impairment can affect survivors’ life planning and
daily life, which may reduce their health-related quality of life
(HRQoL) [6-8].
HRQoL is a multidimensional concept that includes elements
of physical, functional, social, and psychological health as well
as perceived health status and well-being [9]. Many studies
assessing HRQoL in childhood cancer survivors used different
questionnaires or different reference groups or varied in
characteristics of the study population (eg, treatment era, age
of survivors, cancer diagnostic groups), making it difficult to
compare results between studies [10]. Results from large
childhood cancer survivor studies in the United Kingdom
(British Childhood Cancer Survivor Study, BCCSS) [11], the
United States (Childhood Cancer Survivor Study) [12], and
Switzerland (Switzerland Childhood Cancer Survivor Study,
SCCSS) [6] suggest that, on average, childhood cancer survivors
have similar HRQoL compared with the general population.
However, there were significant differences in HRQoL between
subgroups of survivors. Women, survivors with low educational
background, survivors of brain tumors, and survivors who had
undergone radiotherapy had the lowest HRQoL [6,11,12]. It is
still unclear which other factors influence HRQoL and whether
HRQoL in childhood cancer survivors differs among European
countries.
Within the PanCareLIFE project, funded by the European 7th
Framework Program (FP7), we aim to study HRQoL in a large
database of childhood cancer survivors from 5 European
countries using a homogeneous approach to assess and analyze
HRQoL. In particular, we aimed to compare HRQoL in
European childhood cancer survivors with normative data and
between European countries to determine predictors of HRQoL
and describe the effect of hearing and fertility impairment on
HRQoL [13]. This study provides an overview of the design,
data origin, and data collection strategies and summarizes the
characteristics of survivors who participated in this study.
Methods
The PanCareLIFE Research Framework
The European FP7 project PanCareLIFE (grant agreement no.
602030) started in 2013 [14]. Institutions from 10 countries
provided data on more than 15,000 childhood, adolescent, or
young adult cancer survivors. Within the PanCareLIFE
framework, this study focused on long-term HRQoL in
childhood cancer survivors [13]. It was based in the University
Hospitals of Münster (2013-2015) and Bonn (2016-2018). The
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Institute of Social and Preventive Medicine at the University
of Bern provided methodological support and conducted the
analyses. Each institution obtained ethical approval according
to their local and/or national authority regulations before
collecting the data. For all survivors, either written informed
consent was obtained or the ethics committee agreed that an
individual’s consent was not required for this questionnaire
study.
Origin of Data and Inclusion Criteria
The PanCareLIFE HRQoL study population was composed of
6 national or regional cohorts, which had slightly different
inclusion criteria. Table 1 provides an overview of the countries
and institutions that provided data for the PanCareLIFE HRQoL
study.































aUNIBE: University of Bern.
bSCCSS: Swiss Childhood Cancer Survivor Study.
cFNM: Motol Teaching Hospital, Prague, the Czech Republic.
dUHB: University Hospital Brno, the Czech Republic.
eN/A: not applicable.
fCHU-SE: Centre Hospitalier Universitaire de Saint-Étienne, St Étienne, France.
gDCOG LATER: Dutch Childhood Oncology Group Survivor study.
hVIVE: First Basic Survey on Life Situation, State of Health, and Quality of Life of Childhood Cancer Survivors in Germany.
iUKB: Universitätsklinikum, Bonn, Germany.
jUKM: Universitätsklinikum, Münster, Germany.
We combined data from Brno and Prague to 1 Czech cohort.
The identification of eligible survivors depended on the
respective cohort. Switzerland and Germany prospectively
identified the survivors from the national childhood cancer
registry, the Czech Republic and the Netherlands retrospectively
identified the survivors and France implemented both ways of
identification (Table 1) [15,17-19]. The identification of
survivors was population-based in Switzerland, the Rhone-Alpes
region (France), and Germany. In the Netherlands and the Czech
Republic, it was hospital-based, with an estimated coverage of
95% of the national childhood cancer population. Switzerland,
Germany, and the Netherlands enrolled their cohorts before and
France and the Czech Republic after the launch of PanCareLIFE.
Details on the period of data collection and sample
characteristics of each cohort are listed in Table 2.
Table 2. Number of eligible patients, time period of cancer diagnosis, age of survivors at diagnosis, time period of the health-related quality of life
(HRQoL) survey, and age of survivors at HRQoL survey, by country.






Survivors were eligible for the study if they were aged ≤18 years
at the time of diagnosis, had been residents of the respective
country at the time of diagnosis, had a cancer diagnosis
according to the International Classification of Childhood
Cancer, 3rd edition (ICCC-3) [21] or had been diagnosed as
having Langerhans cell histiocytosis, had survived ≥5 years
after cancer diagnosis, were aged ≥18 years at the time of the
questionnaire survey, were not undergoing treatment for cancer
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at the time of the study, and did not refuse to registration in the
national or local childhood cancer cohort. The last criterion did
not apply to Czech survivors because patients were identified
in a clinical routine. We could not calculate the exact age at the
time of survey and the survival time, as we did not receive
information on the day of birth, day of diagnosis, and day of
survey from the institutions because of PanCareLIFE data
protection rules. Therefore, we allowed for a tolerance of 2
months and included survivors who were 2 months older than
18 years at the time of cancer diagnosis, those who survived 2
months less than 5 years, and those who were 2 months younger
than 18 years at the time of the survey.
In addition to the general eligibility criteria, there were
country-specific reasons for the exclusion of eligible survivors
and not all reasons applied to all cohorts. The Czech Republic,
France, and the Netherlands excluded survivors with severe
mental sequelae. In Switzerland and the Czech Republic,
survivors were excluded from invitation because of physicians’
decisions mainly because of palliative care or relapsed disease.
France, the Czech Republic, and Switzerland did not exclude
survivors because of competing surveys. In the Netherlands and
Germany, 2.21% (552/24,993) of survivors could not be
included because they were already enrolled in competing
surveys (Table 3). The French cohort did not include leukemia
survivors.

















1079 (8.89)a677 (12.00)a74 (6.98)a6 (0.19)a252 (8.34)a2088 (8.35)aDied before ques-
tionnaire mailing
0 (0)a11 (0.20)a2 (0.19)a15 (0.48)a0 (0)a28 (0.11)aSevere mental se-
quelae
259 (2.13)a127 (2.25)a0 (0)a8 (0.26)a95 (3.14)a489 (1.96)aLiving abroad
309 (2.54)a16 (0.28)a122 (11.51)a259 (8.28)a148 (4.90)a854 (3.42)aNo address or lost-
to-follow-up
0 (0)a0 (0)a0 (0)a104 (3.33)a14 (0.46)a118 (0.47)aPhysician’s deci-
sion not to invite
the survivorb
286 (2.36)a266 (4.72)a0 (0)a0 (0)a0 (0)a552 (2.21)aCompeting surveys
133 (1.08)a292 (5.18)a11 (1.04)a1159 (37.06)a1 (0.03)a1596 (6.39)aOtherc
10,078 (82.99)a4250 (75.37)a851 (80.28)a1576 (50.40)a2513 (83.13)a19,268 (77.09)aInvited cohort
4549 (45.14)d2074 (48.80)d,e418 (49.12)d461 (29.25)d775 (30.84)d8277 (42.96)dDid not respond to
the invitation
694 (6.89)d0 (0)d,e42 (4.94)d30 (1.90)d148 (5.89)d914 (4.74)dRefused to partici-
pate
109 (1.08)d30 (0.71)d6 (0.71)d56 (3.55)d5 (0.20)d206 (1.07)dShort Form 36 in-
formation incom-
plete for full scor-
ing
4726 (46.89)d2146 (50.49)d385 (45.24)d1029 (65.29)d1585 (63.07)d9871 (51.23)dParticipating cohort
aProportions of survivors from the eligible cohort.
bPhysician’s decision not to invite the survivors because of psychosocial reasons or family problems.
cOther reasons were as follows: patients could not be approached during the study period (the Czech Republic, n=1156), ethical approval not obtained
in time (the Netherlands, n=279), moved to another center (the Netherlands, n=3), unknown case at the time of the study (France, n=1), transgender
(the Netherlands, n=1), did not understand the local language (Switzerland, n=1), unknown reasons (the Czech Republic, n=3; the Netherlands, n=9;
France, n=11; Germany, n=133).
dProportions of survivors from the invited cohort.
eDutch survivors who refused to participate were included in the category Did not respond to the invitation because the Netherlands did not distinguish
between nonresponse and refusal.
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Exposure variables and confounders covered the following
topics: demographic characteristics, socioeconomic measures,
lifestyle, cancer diagnosis, cancer treatment, hearing impairment,
and female fertility impairment.
The outcome variables were the 36 HRQoL questions from the
Short Form 36 (SF-36, version 1 or 2). The Netherlands,
Germany, and the Czech Republic used version 1 of the SF-36,
and Switzerland and France used version 2 [22,23]. Both
versions differ only slightly in a few items, whereas the
psychometric properties are comparable [24]. With the exception
of variables concerning demographic characteristics, cancer
diagnosis, and cancer treatment, all variables were self-reported.
Self-reported confounder variables included living with a partner
(yes or no), education, occupational status, migration
background, alcohol consumption, smoking, and body mass
index. Another substudy of the PanCareLIFE research project
investigated female fertility impairment and coded the data
using 8 different criteria into a binary variable (fertility
impairment: yes or no). The detailed procedure is outlined by
van den Berg et al [25]. Fertility impairment data on male
survivors were unfortunately not available in most of the
cohorts; therefore, we will analyze female survivors only.
Hearing impairment data (yes or no) were collected together
with information on HRQoL via questionnaires. Questions on
hearing impairment differed slightly between data providers.
Data on hearing impairment were not available for the Dutch
cohort. All relevant variables (outcomes, exposures, and
confounders) are listed in Multimedia Appendix 1.
The central PanCareLIFE data center defined a baseline variable
list, including sex, cancer, and treatment-related variables and
a minimal set of information provided for nonparticipants. The
data center collected and harmonized the variables from each
institution. We also recoded a few variables used specifically
for the HRQoL study (eg, on hearing impairment) in cooperation
with the institutions. All partners transferred the data according
to the PanCareLIFE data protection standards.
The sources of cancer-related and treatment information, sources
of self-reported data, and the methods of written questionnaire
assessments differed slightly among the 5 cohorts (Table 4).
Table 4. Sources of cancer-related and treatment data and logistics of paper-pencil questionnaire assessment of health-related quality of life, by country.
Logistics of questionnaire mailing to assess
HRQoLa and sociodemographic data
Source of treatment dataSource of cancer-related dataCountry
Coordinated centrally by SCCSSd. Survivors
were approached by email and phone call re-
minders.
ITTb-based information complement-
ed with ATc information; AT data
retrospectively collected from med-
ical records
Forms sent by clinical sites to Swiss
Childhood Cancer Registry
Switzerland
Coordinated either by UHB or FNM. Survivors
were approached during clinical visits, by email
or phone calls, followed by mailed questionnaire.
AT information, retrospectively
collected from medical records
Clinical records in UHBe and FNMfThe Czech Republic
Coordinated by CHU-SEg. Survivors were ap-
proached mainly by email and phone call re-
minders, sometimes during clinical visits, fol-
lowed by mailed questionnaire.
AT information, retrospectively
collected from medical records
Forms sent by clinical sites of the
Rhône-Alpes region to the Rhône
Alpes Regional Childhood Cancer
Registry
France
Coordinated by DCOG LATERi clinics. Most
survivors were approached by email and few
during clinical visits.
AT information, retrospectively
collected from medical records
DCOGh LATER Registry [17,18]The Netherlands
Coordinated centrally by UKMj or UKBk and
GCCRl. Survivors were approached by mailed
questionnaire.
ITT-based informationForms sent by clinical sites to the
German Childhood Cancer Registry
Germany
aHRQol: health-related quality of life.
bITT: intention to treat.
cAT: as treated.
dSCCSS: Swiss Childhood Cancer Survivor Study.
eUHB: University Hospital Brno, the Czech Republic.
fFNM: Motol Teaching Hospital, Prague, the Czech Republic.
gCHU-SE: Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France.
hDCOG: Dutch Childhood Oncology Group.
iDCOG LATER: Dutch Childhood Oncology Group Survivor study.
jUKM: Universitätsklinikum, Münster, Germany.
kUKB: Universitätsklinikum, Bonn, Germany.
lGCCR: German Childhood Cancer Registry.
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Data on HRQoL and HRQoL-specific exposure variables and
self-reported confounders were assessed using the same
questionnaire. An exception were the Dutch survivors, who
answered the questionnaire on HRQoL on average 4 years later
than the questions on sociodemographic characteristics and
lifestyle for the purpose of their national Dutch Childhood
Oncology Group Survivor (DCOG LATER) study.
SF-36 Data From the General Population
Country-specific reference data from the general population did
not exist for Switzerland, France, and the Czech Republic at
the time of the study. We used the German SF-36 version 1
normative data from 1998 for norm-based scoring of data from
all participating countries [26]. This norm-based scoring allowed
us to compare the HRQoL between countries [24]. We also
scored HRQoL raw data with more recent SF-36 version 2
normative data from Germany (2008-2011) [24] and from
Switzerland (2015-2016) [27].
Statistical Analyses
We compared survivors who participated in the survey with
those who did not participate using chi-square tests. We used
the software package Stata (version 14, StataCorp) for all
analyses.
For all future analyses, we documented the planned statistical
approaches for all HRQoL-related research questions of
PanCareLIFE in a statistical analysis plan before we received
the data from the central data center. In brief, SF-36 consists of
36 items (questions), which use a 2- to 6-point Likert scale,
depending on the item. Between 2 and 10 items can be
summarized into 1 of the 8 scales (physical functioning, role
physical, bodily pain, general health, vitality, social functioning,
role emotional, and mental health) and further into 2 summary
scores (Physical Component Summary and Mental Component
Summary). Because we will perform comparisons with both
version 1 and version 2 normative data, we will transform all
scales into the respective version with an algorithm provided
by the developer of SF-36 [23,24,26]. We will convert raw
scores into T-scores (mean 50, SD 10), and depending on the
normative data used, we will stratify for subgroups, for example,
age and sex. Higher scores indicate better HRQoL. Survivors
with >50% missing data in any of the SF-36 scales will be
excluded from the analyses. We will implement appropriate
measures to deal with missing values, including imputation
procedures. We will use regression analyses with HRQoL as
an outcome variable to address all research questions to (1)
compare HRQoL in European childhood cancer survivors with
normative data and between European countries and to
determine predictors of HRQoL, (2) describe the effect of
hearing impairment on HRQoL, and (3) describe the effect of
fertility impairment on HRQoL. We will include country,
gender, and age in all multivariable models. We will also include
the most important risk factors as defined by a selection criterion
of P<.05 in the univariable regression. Multimedia Appendix
1 gives an overview of the variables that we plan to include in
the regression analyses. If HRQoL scores have a skewed
distribution, we will run logistic regressions (poor HRQoL vs
normal or high HRQoL) and define poor HRQoL and high
HRQoL, respectively, as scores below [11] and above the 10th
percentile of the control population.
We will analyze subcohorts depending on the research question
(Multimedia Appendix 2). For the analyses of differences in
HRQoL between participating countries and predictors of
HRQoL and for the analyses of the effect of hearing on HRQoL,
we will use 2 main subsets for the analysis. In the first, we will
include all survivors aged ≥25 years at the time of the study
from all participating countries. The second subset will include
survivors aged <25 years from all countries except Germany
because Germany did not collect data in this age group. For the
analyses on the effect of fertility impairment on HRQoL, we
will investigate female survivors aged ≥25 years only. We will
describe the detailed procedure in the respective publication of
each research question.
Results
We identified 24,993 eligible 5-year childhood cancer survivors
(Table 3). Of those, 5725 had died before the questionnaire
survey, had severe mental problems, were living abroad at the
time of the study, had no available contact data (lost to
follow-up), were enrolled in competing surveys, their physicians
decided not to invite them, or for other reasons. Of the 19,268
survivors who received an invitation to the HRQoL survey,
9192 did not respond or refused to participate and 206 had
incomplete SF-36 information, preventing full scoring. In total,
9871 survivors (4725 men and 5146 women) participated in the
HRQoL analyses, thus resulting in response rates of 39.50%
(9871/24,993) of eligible survivors and of 51.23% (9871/19,268)
of invited survivors. Of the 9871 participating survivors, almost
half were from Germany 4726 (47.88%), 2146 (21.74%) from
the Netherlands, 1585 (16.06%) from Switzerland, 1029
(10.42%) from the Czech Republic, and 385 (3.90%) from
France (Table 5).
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All data providers com-
bined (N=9871), n (%)
Country
Sex
2311 (48.90)1076 (50.14)167 (43.38)347 (33.72)824 (51.99)4725 (47.87)Male
2415 (51.10)1070 (49.86)218 (56.62)682 (66.28)a761 (48.01)5146 (52.13)Female
Age at the time of survey (years)
0 (0)353 (16.45)131 (34.03)427 (41.50)725 (45.74)1636 (16.57)18 to <25
1879 (39.76)346 (16.12)123 (31.95)275 (26.72)374 (23.60)2997 (30.36)25 to <30
1566 (33.14)402 (18.73)93 (23.90)164 (15.94)239 (15.08)2463 (24.95)30 to <35
791 (16.74)363 (16.92)33 (8.57)104 (10.11)146 (9.21)1437 (14.56)35 to <40
414 (8.76)301 (14.03)6 (1.56)49 (4.76)63 (3.97)833 (8.44)40 to <45
76 (1.61)381 (17.75)0 (0)10 (0.97)38 (2.40)505 (5.12)45-69
Age at cancer diagnosis (years)
1379 (29.18)936 (43.62)173 (44.94)289 (28.09)424 (26.75)3201 (32.43)0 to <5
1332 (28.18)595 (27.73)97 (25.19)196 (19.05)352 (22.21)2572 (26.06)5 to <10
1989 (42.09)468 (21.81)115 (29.87)336 (32.65)540 (34.07)3448 (34.93)10 to <15
26 (0.55)147 (6.85)0 (0)208 (20.21)269 (16.97)650 (6.58)15-18
Period of cancer diagnosis
982 (20.78)711 (33.13)0 (0)53 (5.15)340 (21.45)2086 (21.13)1963 to <1985
2651 (56.09)764 (35.60)261 (67.79)283 (27.50)721 (45.49)4680 (47.41)1985 to <1995
1093 (23.13)671 (31.27)124 (32.21)501 (48.69)403 (25.43)2792 (28.28)1995 to <2005
0 (0)0 (0)0 (0)192 (18.66)121 (7.63)313 (3.17)2005-2010
Time since cancer diagnosis (years)
0 (0)0 (0)0 (0)164 (15.94)291 (18.36)455 (4.61)5 to <10
324 (6.86)0 (0)4 (1.04)226 (21.96)281 (17.73)835 (8.46)10 to <15
915 (19.36)450 (20.97)134 (34.81)283 (27.50)397 (25.05)2179 (22.07)15 to <20
1363 (28.84)439 (20.46)209 (54.29)160 (15.55)332 (20.95)2503 (25.36)20 to <25
1279 (27.06)393 (18.31)38 (9.87)130 (12.63)183 (11.55)2023 (20.49)25 to <30
844 (17.86)331 (15.42)0 (0)43 (4.18)84 (5.30)1302 (13.19)30 to <35
1 (0.02)533 (24.84)0 (0)23 (2.24)17 (1.07)574 (5.82)35-54
Cancer diagnosis (ICCC-3)b
1673 (35.40)724 (33.74)0 (0)c267 (25.95)492 (31.04)3157 (31.97)I Leukemias
1026 (21.71)349 (16.26)83 (21.56)266 (25.85)351 (22.15)2075 (21.02)II Lymphomas
643 (13.61)256 (11.93)96 (24.94)125 (12.15)236 (14.89)1356 (13.74)III CNSd tumors
174 (3.68)118 (5.50)52 (13.51)46 (4.47)51 (3.22)440 (4.47)IV Neuroblas-
toma
103 (2.18)10 (0.47)9 (2.34)19 (1.85)32 (2.02)172 (1.74)V Retinoblas-
toma
286 (6.05)239 (11.14)52 (13.51)81 (7.87)80 (5.05)738 (7.48)VI Renal tumors
16 (0.34)16 (0.75)9 (2.34)11 (1.07)9 (0.57)61 (0.62)VII Hepatic tu-
mors
286 (6.05)116 (5.41)30 (7.79)62 (6.03)94 (5.93)588 (5.96)VIII Bone tumors
309 (6.54)164 (7.64)26 (6.75)55 (5.34)99 (6.25)654 (6.63)IX Soft tissue
sarcomas
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All data providers com-
bined (N=9871), n (%)
Country
163 (3.45)88 (4.10)15 (3.90)60 (5.83)60 (3.79)386 (3.91)X Germ cell tu-
mors
44 (0.93)30 (1.40)13 (3.38)20 (1.94)23 (1.45)130 (1.32)XI Epithelial
neoplasms and
melanomas
3 (0.06)36 (1.68)0 (0)17 (1.65)58 (3.66)114 (1.15)Other malignant
neoplasmse
Subsequent tumorf
374 (7.91)149 (6.94)14 (3.64)64 (6.22)45 (2.84)646 (6.54)Yes
4352 (92.09)1997 (93.06)371 (96.36)965 (93.78)1540 (97.16)9225 (93.46)No
Cancer treatment
81(1.71)213 (9.93)92 (23.90)66 (6.41)190 (11.99)642 (6.50)Surgery only
17(0.36)26 (1.21)2 (0.52)2 (0.19)2 (0.13)49 (0.50)Radiotherapy on-
ly
882 (18.66)639 (29.78)35 (9.09)176 (17.10)354 (22.33)2086 (21.13)Chemotherapy
only
50 (1.06)113 (5.27)13 (3.38)32 (3.11)77 (4.86)285 (2.89)Surgery and radio-
therapy
517 (10.94)529 (24.65)129 (33.51)214 (20.80)348 (21.96)1737 (17.60)Surgery and
chemotherapy
1294 (27.38)257 (11.98)30 (7.79)249 (24.20)145 (9.15)1975 (20.01)Radiotherapy and
chemotherapy
797 (16.86)343 (15.98)79 (20.52)261 (25.36)367 (23.15)1847 (18.71)Radiotherapy,
chemotherapy,
and surgery
6 (0.13)18 (0.84)3 (0.78)3 (0.29)16 (1.01)46 (0.47)No surgery,
chemotherapy, or
radiotherapy
1082 (22.89)8 (0.37)2 (0.52)26 (2.53)86 (5.43)1204 (12.20)Complete treat-
ment information
not available
Hematopoietic stem cell transplantation
249 (5.27)4 (0.19)0 (0)3 (0.29)51 (3.22)307 (3.11)Unknown
47 (0.99)50 (2.33)25 (6.49)120 (11.66)65 (4.10)307 (3.11)Yes
4430 (93.74)2092 (97.48)360 (93.51)906 (88.05)1469 (92.68)9257 (93.78)No
aThe Czech cohort included a higher proportion of women than other countries, because women were prioritized during recruitment as they were also
part of an associated PanCareLIFE study on female fertility.
bICCC-3: International Classification of Childhood Cancer, 3rd edition.
cPercentages of French cohort varied from those of other countries because the French cohort did not include survivors of leukemia and CNS tumors
represented the largest of diagnostic groups.
dCNS: central nervous system.
eICCC-3 main group XII (Other and unspecified malignant neoplasms) and Langerhans cell histiocytosis but not benign and in situ tumors and tumor-like
lesions or unclassified survivors.
fAll subsequent tumors registered in national registry until the start of the study.
Most survivors were diagnosed as having cancer between the
ages of 10 and 14 years (3488/9871, 34.93%) or <5 years
(3201/9871, 32.43%). Almost half (4680/9871, 47.41%) were
diagnosed as having cancer between 1985 and 1994, most were
survivors of leukemia (3157/9871, 31.97%), lymphoma
(2075/9871, 21.02%), or CNS tumors (1356/9871, 13.74%),
had no history of a subsequent tumor (9225/9871, 93.46%), and
received chemotherapy with or without surgery and/or
radiotherapy (7645/9871, 77.45%). More than half (5460/9871,
55.31%) of the participants were aged 25 to 34 years at the time
of the HRQoL study.
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Response rates differed between countries. The proportions of
eligible survivors who were invited to participate were 83.13%
(2513/3023) in Switzerland and 82.99% (10,078/12,144) in
Germany, 80.28% (861/1060) in France, 75.37% (4250/5639)
in the Netherlands, and 50.40% (1576/3127) in the Czech
Republic (Table 3). The proportion of responders was highest
in the Czech Republic, with 65.3% (1029/3127) and lowest in
France (385/1060, 45.2%).
Participants were more often women, slightly younger at the
time of the survey, and slightly older at cancer diagnosis; their
cancer diagnosis tended to be in more recent years, and they
were more often survivors of leukemia or lymphoma and less
often survivors of CNS tumors than nonparticipants (Table 6).
The Czech participants had the highest proportion of women
(682/3127, 66.3%) because women were prioritized during
recruitment as they were also part of an associated PanCareLIFE
study on female fertility [25]. In other countries, the proportion
of women ranged between 48.0% (761/3023, Switzerland) and
56.6% (218/1060, France).
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Table 6. Comparison of participants and nonparticipants.




<.001Age at the time of survey (years)
2245 (14.79)1636 (16.57)18 to <25
4355 (28.69)2997 (30.36)25 to <30
3886 (25.60)2463 (24.95)30 to <35
2496 (16.44)1437 (14.56)35 to <40
1399 (9.22)833 (8.44)40 to <45
798 (5.26)505 (5.12)45-69
.005Age at the time of cancer diagnosis (years)
5075 (33.43)3201 (32.43)0 to <5
4055 (26.71)2572 (26.06)5 to <10
4977 (32.79)3448 (34.93)10 to <15
1072 (7.06)650 (6.58)15-18
.004Period of cancer diagnosis
3500 (23.06)2086 (21.13)1963 to <1985
7064 (46.54)4680 (47.41)1985 to <1995
4128 (27.20)2792 (28.28)1995 to <2005
487 (3.21)313 (3.17)2005-2010
<.001Time since cancer diagnosis (years)
679 (4.47)455 (4.61)5 to <10
1024 (6.75)835 (8.46)10 to <15
2986 (19.67)2179 (22.07)15 to <20
3738 (24.63)2503 (25.36)20 to <25
3513 (23.14)2023 (20.49)25 to <30
2335 (15.38)1302 (13.19)30 to <35
904 (6.96)574 (5.82)35-54
<.001Cancer diagnosis (ICCC-3)b
4398 (28.97)3157 (31.97)I Leukemias
3015 (19.86)2075 (21.02)II Lymphomas
2659 (17.52)1356 (13.74)III CNSc tumors
696 (4.59)440 (4.47)IV Neuroblastoma
320 (2.11)172 (1.74)V Retinoblastoma
983 (6.48)738 (7.48)VI Renal tumors
101 (0.67)61 (0.62)VII Hepatic tumors
983 (6.48)588 (5.96)VIII Bone tumors
954 (6.28)654 (6.63)IX Soft tissue sarcomas
644 (4.24)386 (3.91)X Germ cell tumors
279 (1.84)130 (1.32)XI Epithelial neoplasms and melanomas
147 (0.97)114 (1.15)Other malignant neoplasmsd
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P valueaNonparticipants (n=15,179), n (%)Participants (n=9871), n (%)Characteristics
<.001Treatment
1240 (8.17)642 (6.50)Surgery only
87 (0.57)49 (0.50)Radiotherapy only
2551 (16.81)2086 (21.13)Chemotherapy only
431 (2.84)285 (2.89)Surgery and radiotherapy
2048 (13.49)1737 (17.60)Surgery and chemotherapy
2580 (17.00)1975 (20.01)Radiotherapy and chemotherapy
2075 (13.67)1847 (18.71)Radiotherapy, chemotherapy, and surgery
76 (0.50)46 (0.47)No surgery, chemotherapy, or radiotherapy
4091 (26.95)1204 (12.20)Complete treatment information not available
aP values were derived from Pearson chi-square tests.
bICCC-3: International Classification of Childhood Cancer, 3rd edition.
cCNS: central nervous system.
dICCC-3 main group XII (other and unspecified malignant neoplasms) and Langerhans cell histiocytosis but not benign and in situ tumors and tumor-like
lesions or unclassified survivors.
Discussion
Central Message
PanCareLIFE has successfully constructed a large population
of 9871 childhood cancer survivors with comprehensive data
to assess HRQoL and its predictors. This rich data set of survivor
cohorts from 5 different countries will allow in-depth
investigation of the differences in HRQoL between countries,
including the effect of female fertility and hearing impairment
on HRQoL. The sample size and the wide range of treatment
era, type of diagnosis, and age at diagnosis provide an excellent
basis for risk stratification. It will thereby provide new scientific
information on risk factors for impaired HRQoL after childhood
cancer. This study will be the first to estimate the association
between well-defined female fertility information and HRQoL
with ample statistical power. Our results will help caregivers
to identify survivors at risk for decreased HRQoL and will
contribute to the development of evidence-based interventions
toward better HRQoL of future childhood cancer survivors. Our
data allow us to investigate similar predictors of HRQoL as in
previous studies [6,11] (except for annual income) and, in
addition, the role of female fertility impairment.
Strengths and Limitations
This study is one of the largest studies worldwide to examine
HRQoL and its predictors in childhood cancer survivors. It is,
in terms of size, comparable with large studies from the United
States (CCSS) [12] and the United Kingdom (BCCSS) [11].
This study combines a series of population-based or regionally
well-defined cohorts from different European countries or
regions. This will allow comparisons between national cohorts
and representative in-depth analyses of HRQoL in survivors
and their influencing factors. The central data center processed
the raw data from all institutions to minimize coding and data
cleaning errors before data pooling.
We faced some challenges when assembling the data from 6
institutions from 5 countries, as recruitment and study design
differed between countries. Some countries had specific
exclusion criteria before they invited the survivors to the survey,
which may have led to selection biases. The Netherlands, the
Czech Republic, and France excluded survivors with severe
mental sequelae and other severe impairments. However, these
were only a few patients (only 0.1% of eligible patients, n=28),
and therefore, a potential bias toward an overestimation of
HRQoL in these countries is negligible. Germany did not contact
survivors <25 years on the date of the survey, France did not
include survivors of childhood leukemia, and the Netherlands
did not send data on hearing impairment. Depending on the
research question, we will stratify the overall data set by age at
survey (18-24 years and ≥25 years) and/or by country (including
or excluding Germany and/or France and/or the Netherlands).
The time elapsed between diagnosis and survey differed between
countries. In Switzerland and the Czech Republic, survivors
received a questionnaire already ≥5 years after diagnosis,
whereas in Germany, France, and the Netherlands, it was much
longer (≥10 years). However, in the SCCSS, the time since
diagnosis did not influence HRQoL after adjusting for age at
the time of the study [6]. We will, therefore, include age at the
time of diagnosis and age at the time of the survey in all
multivariable analyses. The Motol Teaching Hospital in Prague
preferred female survivors to participate in the study. A high
proportion of women may lead to the underestimation of HRQoL
because women reported lower HRQoL than men in both CCSS
[12] and BCCSS [11]. We will adjust for sex in all regression
models and stratify the results by sex.
Of all countries, France had the highest percentage of survivors
who were lost to follow-up and the Netherlands had the lowest.
In the Netherlands, the proportion of 5-year survivors who died
before the mailing of the questionnaire was highest, most
probably because the Dutch cohort had the longest follow-up.
Age at the time of study was a predictor for some domains of
HRQoL in the SCCSS [6] and in a study from the European
Organization for Research and Treatment of Cancer [28] pooling
data from the general population. In future analyses, we will
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adjust for age at the time of the survey in multivariable
regression models.
Different assessment logistics among the countries may have
influenced response rates. In the Czech cohort, where most
survivors were asked to participate during clinical follow-up
visits, the participation rate was higher than in Switzerland, the
Netherlands, or Germany, who invited all eligible participants
via letters. Survivors who have a high risk for late effects are
followed up with clinical visits more often than those with lower
risk [29]. In the SCCSS, survivors with late effects were at risk
for low HRQoL [6]. Therefore, the different sampling
procedures in the Czech cohort could have resulted in a lower
HRQoL score compared with the other countries. Differences
in mentality and general willingness to take part in surveys may
also explain the differences in response rates.
The participating survivors differed only slightly from those
who did not respond, suggesting that bias from selective
response may not be large. The higher proportion of
participating women than men reflects a commonly observed
self-selection bias in questionnaire health surveys [30]. The
frequencies of observed diagnostic groups are similar to those
reported from population-based cancer registries, with the
following exceptions: more survivors of lymphoma and less
survivors of brain tumors participated, reflecting a
prognosis-based disease bias.
The countries contributing to this study assessed treatment data
differently: most countries collected as-treated data
retrospectively from medical records. Switzerland
complemented intention-to-treat (ITT) data, with retrospective
data from medical records. Germany used solely ITT data from
a study protocol database, which did not have treatment data
information for 23% of the survivors.
Overall, the limitations refer to different aspects of the data and
are mostly specific for each country; therefore, we will provide
overall and country-specific results and perform sensitivity
analyses excluding countries with specific properties. We will
also include a careful evaluation of the differences in data
ascertainment and data quality between countries when
interpreting the results for specific research questions.
Conclusions and Prospects for Further Research
With careful interpretation, the large data set of this
PanCareLIFE study provides a unique opportunity to study
long-term HRQoL among childhood cancer survivors across
Europe. It will contribute to the knowledge on HRQoL after
childhood cancer while acknowledging the differences between
countries in treatment traditions and long-term care. It will also
allow the investigation of the role of female fertility and hearing
impairment on HRQoL. The results may uncover unknown risk
factors for reduced HRQoL and will help inform clinicians
about certain groups of survivors who have greater needs for
counseling and psychological support to obtain the best possible
HRQoL.
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Overview of outcome variables, exposures, and confounders for the regression analyses.
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Flow diagram of the study sample, from eligible survivors to those included in the health-related quality of life (HRQoL) analyses,
and planned subsamples.
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